Abstract 4365304: Prolonged QT Interval After Cryptogenic Stroke and Risk of Recurrent Stroke in the ARCADIA Trial

B Brian Boursiquot (Columbia University Medical Center, New York, New York, United States) A Adi Elias (University of California San Francisco, San Francisco, California, United States) H Hooman Kamel R Richard Kronmal (University of Washington, Seattle, Washington, United States) G Gregory Marcus (University of California, San Francisco, San Francisco, California, United States) M Marco Di Tullio (Columbia University Medical Center, New York, New York, United States) D David Tirschwell (University of Washington, Seattle, WA, USA.) M Mitchell Elkind (American Heart Association, Dallas, Texas, United States) W W Longstreth (Harborview Medical Center, Seattle, Washington, United States) E Elsayed Soliman (Wake Forest School of Medicine, Winston-Salem, North Carolina, United States)

Abstract

Introduction: Prolonged QT interval has been associated with first stroke of any type in the general population. Whether QT prolongation predicts recurrent stroke is unknown. Hypothesis: We hypothesized that QT prolongation would be associated with increased risk of recurrent stroke in individuals who recently suffered a cryptogenic stroke. Methods: The Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial randomized individuals with cryptogenic stroke and atrial cardiopathy to apixaban versus aspirin to assess the prevention of recurrent strokes. We excluded participants with missing QT interval data and those who had ventricular conduction defects or pacemakers. The baseline electrocardiogram (ECG) was the first technically adequate ECG to be done after stroke onset. QT interval was corrected for heart rate (QTc) using a cohort-specific correction formula, as well as the Framingham, Hodges, Bazett, and Fridericia formulae. For each QTc variable, prolonged QTc was defined as >450 ms in men or >460 ms in women. Cox proportional hazards models were used to assess the association between QTc and recurrent stroke. Models were adjusted for randomization arm, age, sex, race, smoking, hypertension, diabetes, prior stroke, and N-terminal pro-B-type natriuretic peptide. Results: Among 881 participants, 139 (15.8%) had a prolonged cohort-specific QTc. Over a mean of 1.8 years, 62 recurrent strokes of any type occurred (crude rate 7.0%, annualized rate 3.9% per year). After multivariable adjustment, prolongation of cohort-specific QTc was associated with decreased risk of stroke (hazard ratio [95% confidence interval] = 0.72 [0.54-0.95] per standard deviation and 0.16 [0.04-0.64] for prolonged vs. normal QTc). These findings were consistent across all methods of QT correction ( Table) . Accounting for QRS duration, incident atrial fibrillation, and the competing risk of death did not change the results. Conclusions: In a population with recent cryptogenic stroke and atrial cardiopathy, QTc prolongation was associated with a lower risk of recurrent stroke. These findings contrast with the association observed between QTc prolongation and stroke in the general population, which may reflect selection bias or bias from ECGs obtained in the acute phase of stroke. If replicated, these findings suggest that repolarization markers like QTc may play different roles in stroke risk stratification for first versus recurrent stroke.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (10)

B

Brian Boursiquot

Columbia University Medical Center, New York, New York, United States

A

Adi Elias

University of California San Francisco, San Francisco, California, United States

H

Hooman Kamel

R

Richard Kronmal

University of Washington, Seattle, Washington, United States

G

Gregory Marcus

University of California, San Francisco, San Francisco, California, United States

M

Marco Di Tullio

Columbia University Medical Center, New York, New York, United States

D

David Tirschwell

University of Washington, Seattle, WA, USA.

M

Mitchell Elkind

American Heart Association, Dallas, Texas, United States

W

W Longstreth

Harborview Medical Center, Seattle, Washington, United States

E

Elsayed Soliman

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States